|Day's Range||129.54 - 134.40|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-237.64|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Despite rampant rumors, Gilead is not likely to acquire either Incyte or Vertex. Here's why.
Gilead could fill a hole in its portfolio by acquiring Incyte, an analyst suggested Friday, offering one caveat — Vertex would still be a less risky bet.
A key hepatitis C drug from Gilead could top Wall Street's Q2 expectations, but investors want to hear more about potential M&A activity.